- Home
- PAGP vs ZLAB Comparison
PAGP vs ZLAB Comparison
Compare PAGP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAGP
- ZLAB
- Stock Information
- Founded
- PAGP 2013
- ZLAB 2013
- Country
- PAGP United States
- ZLAB China
- Employees
- PAGP N/A
- ZLAB N/A
- Industry
- PAGP Natural Gas Distribution
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PAGP Energy
- ZLAB Health Care
- Exchange
- PAGP Nasdaq
- ZLAB Nasdaq
- Market Cap
- PAGP 3.3B
- ZLAB 3.2B
- IPO Year
- PAGP 2013
- ZLAB 2017
- Fundamental
- Price
- PAGP $17.65
- ZLAB $26.40
- Analyst Decision
- PAGP Hold
- ZLAB Buy
- Analyst Count
- PAGP 8
- ZLAB 6
- Target Price
- PAGP $19.86
- ZLAB $57.22
- AVG Volume (30 Days)
- PAGP 1.4M
- ZLAB 613.7K
- Earning Date
- PAGP 11-05-2025
- ZLAB 11-06-2025
- Dividend Yield
- PAGP 8.62%
- ZLAB N/A
- EPS Growth
- PAGP N/A
- ZLAB N/A
- EPS
- PAGP 0.69
- ZLAB N/A
- Revenue
- PAGP $47,796,000,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- PAGP N/A
- ZLAB $41.80
- Revenue Next Year
- PAGP $11.23
- ZLAB $49.93
- P/E Ratio
- PAGP $30.19
- ZLAB N/A
- Revenue Growth
- PAGP N/A
- ZLAB 32.56
- 52 Week Low
- PAGP $16.61
- ZLAB $23.82
- 52 Week High
- PAGP $22.31
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- PAGP 47.04
- ZLAB 30.48
- Support Level
- PAGP $16.83
- ZLAB $27.81
- Resistance Level
- PAGP $17.81
- ZLAB $29.77
- Average True Range (ATR)
- PAGP 0.30
- ZLAB 1.24
- MACD
- PAGP 0.09
- ZLAB -0.38
- Stochastic Oscillator
- PAGP 75.89
- ZLAB 4.18
About PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.